Purpose There is an unmet need for effective renal sparing treatments for upper tract
urothelial carcinoma (UTUC). Gemcitabine/Docetaxel (Gem/Doce) has shown favorable …

PURPOSE Neoadjuvant chemotherapy (NAC) has proven survival benefits for patients with
invasive urothelial carcinoma of the bladder, yet its role for upper tract urothelial carcinoma …

Introduction Nephroureterectomy is commonly performed for high-grade (HG) upper tract
(UT) urothelial carcinoma (UC). However, some patients may benefit from a de-escalation of …

Background Retrospective evaluation of the effectiveness and adverse events (AEs) of a
sequential chemotherapy regimen using gemcitabine+ carboplatin (GCarbo) followed by …

440 Background: Neoadjuvant chemotherapy (NAC) has proven survival benefits for
invasive urothelial carcinoma of the bladder, yet its role in upper tract urothelial carcinoma …

280 Background: Compared to MVAC, HD-MVAC achieves significantly higher complete
response rates in patients (pts) with metastatic bladder cancer. Based on current literature …

Objectives We evaluated pathologic and survival outcomes of GC (gemcitabine/cisplatin)
and methotrexate/vinblastine/doxorubicin/cisplatin (M-VAC) neoadjuvant chemotherapy …

INTRODUCTION AND OBJECTIVES: Neoadjuvant chemotherapy (NAC) has established
survival benefits prior to radical cystectomy for invasive urothelial carcinoma, yet its role in …

Methods: This retrospective chart review examined all patients having a RC between
January 1, 2007 and June 30, 2011. We collected patient demographics, pre-treatment …

Introduction Among patients with high-grade (HG) non-muscle invasive urothelial carcinoma
(UC) of the bladder, prostatic urethral involvement occurs in 16-39%. Management of …